Oppenheimer downgraded Dyne Therapeutics (DYN) to Perform from Outperform.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne announces additional one-year data from ACHIEVE study
- Dyne Therapeutics Elects Brian Posner to Board
- Dyne Therapeutics receives orphan drug designation in Japan for DYNE-251 in DMD
- Keurig Dr Pepper buys JDE Peet’s, Thoma Bravo to acquire Verint: Morning Buzz
- Video: RH, Wayfair slip after Trump furniture tariff probe threat